International Journal of Cancer Management

Published by: Kowsar
Crossmark

Predictive Power of Human Chorionic Gonadotropin in Post-Molar Gestational Trophoblastic Neoplasia: A Longitudinal Roc Analysis

Azin Khosravirad 1 , Farid Zayeri 1 , * , Ahmad Reza Baghestani 1 , Moein Yoosefi 1 and Mahmood Bakhtiyari 2
Authors Information
1 Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Epidemiology and Biostatistics, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: September 2017, 10 (9); e9015
  • Published Online: September 30, 2017
  • Article Type: Research Article
  • Received: September 18, 2016
  • Accepted: September 19, 2017
  • DOI: 10.5812/ijcm.9015

How to Cite: Khosravirad A, Zayeri F, Baghestani A R, Yoosefi M, Bakhtiyari M. Predictive Power of Human Chorionic Gonadotropin in Post-Molar Gestational Trophoblastic Neoplasia: A Longitudinal Roc Analysis, Int J Cancer Manag. 2017 ; 10(9):e9015. doi: 10.5812/ijcm.9015.

Abstract
Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010; 376(9742) : 717 -29 [DOI][PubMed]
  • 2. Hall WJ. Evaluation of serial beta-human chorionic gonadotrophin levels after primary treatment of molar pregnancies: can the follow-Up for surveillance of persistence or malignant transformation be shortened? 2012;
  • 3. Jauniaux E. Ultrasound diagnosis and follow-up of gestational trophoblastic disease. Ultrasound Obstet Gynecol. 1998; 11(5) : 367 -77 [DOI][PubMed]
  • 4. Mangili G, Garavaglia E, Cavoretto P, Gentile C, Scarfone G, Rabaiotti E. Clinical presentation of hydatidiform mole in northern Italy: has it changed in the last 20 years? American J Obstet Gynecol. 2008; 198(3) : 301 -2
  • 5. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010; 203(6) : 531 -9 [DOI][PubMed]
  • 6. Chiang J, Berek J, Goff B, Falk S. Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis. 2011;
  • 7. Benedet JL. Staging classifications and clinical practice guidelines for gynaecological cancers. Int J Gynecol Obstetrics. 2000; 70(2) : 207 -312 [DOI]
  • 8. Kerkmeijer LG, Wielsma S, Massuger LF, Sweep FC, Thomas CM. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands. Gynecol Oncol. 2007; 106(1) : 142 -6 [DOI][PubMed]
  • 9. Feltmate CM, Batorfi J, Fulop V, Goldstein DP, Doszpod J, Berkowitz RS. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol. 2003; 101(4) : 732 -6 [PubMed]
  • 10. van Trommel NE, Sweep FC, Schijf CP, Massuger LF, Thomas CM. Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios. Eur J Endocrinol. 2005; 153(4) : 565 -75 [DOI][PubMed]
  • 11. van Trommel NE, Ngo Duc H, Massuger LF, Schijf CP, Sweep CG, Thomas CM, et al. Early identification of persistent trophoblastic disease with serum hCG concentration ratios. Int J Gynecol Cancer. 2008; 18(2) : 318 -23 [DOI][PubMed]
  • 12. Kang WD, Choi HS, Kim SM. Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole. Gynecol Oncol. 2012; 124(2) : 250 -3 [DOI][PubMed]
  • 13. Schlaerth JB, Morrow CP, Kletzky OA, Nalick RH, D'Ablaing GA. Prognostic characteristics of serum human chorionic gonadotropin titer regression following molar pregnancy. Obstet Gynecol. 1981; 58(4) : 478 -82 [PubMed]
  • 14. Shigematsu T, Kamura T, Saito T, Kaku T, Nakano H, Kinugawa N. Identification of persistent trophoblastic diseases based on a human chorionic gonadotropin regression curve by means of a stepwise piecewise linear regression analysis after the evacuation of uneventful moles. Gynecol Oncol. 1998; 71(3) : 376 -80 [DOI][PubMed]
  • 15. Yedema KA, Verheijen RH, Kenemans P, Schijf CP, Borm GF, Segers MF, et al. Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve. American J Obstet Gynecol. 1993; 168(3) : 787 -92
  • 16. Curry SL, Schlaerth JB, Kohorn EI, Boyce JB, Gore H, Twiggs LB, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study). Am J Obstet Gynecol. 1989; 160(4) : 805 -9 [PubMed]
  • 17. Cole LA. Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites. Clin Chem. 1997; 43(12) : 2233 -43 [PubMed]
  • 18. Liu D, Albert PS. Combination of longitudinal biomarkers in predicting binary events. Biostatistics. 2014; 15(4) : 706 -18 [DOI][PubMed]
  • 19. Vetter V. Management of gestational trophoblastic disease. J American Academy Physician Assistant. 2013; 26(3) : 31 -2 [DOI]
  • 20. Kimiaee P, Ashrafi-vand S, Mansournia MA, Bakhtiyari M, Mirzamoradi M, Bakhtiyari Z. Predictive values of different forms of human chorionic gonadotropin in postmolar gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2014; 24(9) : 1715 -22 [DOI][PubMed]
  • 21. Mousavi AS, Karimi S, Modarres Gilani M, Akhavan S, Rezayof E. Does postevacuation β-human chorionic gonadotropin level predict the persistent gestational trophoblastic neoplasia? Isrn Obstetric Gynecol. 2014;
  • 22. Kim BW, Cho H, Kim H, Nam EJ, Kim SW, Kim S, et al. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2012; 160(1) : 100 -5 [DOI][PubMed]
  • 23. Lybol C, Sweep FC, Ottevanger PB, Massuger LF, Thomas CM. Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolar gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2013; 23(6) : 1150 -6 [DOI][PubMed]
  • 24. Behtash N, Ghaemmaghami F, Honar H, Riazi K, Nori A, Modares M, et al. Is normal beta-hCG regression curve helpful in the diagnosis of persistent trophoblastic disease? Int J Gynecol Cancer. 2004; 14(5) : 980 -3 [DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments